Two drugs, dasatinib and quercetin, in combination with CAR T-cell therapy (ciltacabtagene autoleucel), to treat multiple myeloma that has come back (relapsed) or not gotten better with treatment (refractory)

To find out if dasatinib and quercetin, in combination with CAR T-cell therapy, is safe and works well to treat multiple myeloma that has relapsed or is refractory

CAR stands for chimeric antigen receptors and T stands for T cells, a type of immune cell. This treatment helps your own immune system find and destroy cancer cells.
Ciltacabtagene autoleucel is a type of CAR T-cell therapy that targets BCMA on certain cells.
Cyclophosphamide and fludarabine are chemotherapy (chemo) drugs that block the growth of cancer cells.
Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL in certain cells. 
Quercetin is a dietary supplement that is used for its antioxidant and anti-inflammatory effects.

To make CAR T cells, T cells are collected from you by apheresis. Apheresis is a process to collect cells from the bloodstream using a needle similar to when you donate blood. The T cells are genetically modified to grow special proteins called CARs. CARs help T cells find the cancer cells. The CAR T cells are grown in a lab until there are millions of them. Then, they’re given back to you to find and destroy the cancer cells.
 
Before the CAR T-cell infusion, you’ll get:

Then, the CAR T cells are given to you through an IV infusion. 

After the CAR T-cell infusion, you'll get:

The clinical trial doctors will watch you closely over 2 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 15 years.

The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this combination to treat multiple myeloma that has relapsed or is refractory is new and unproven. 

Watch a video about CAR T-Cell Therapy